Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diag...
Saved in:
Published in | PLoS medicine Vol. 10; no. 9; p. e1001510 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
01.09.2013
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
ISSN | 1549-1676 1549-1277 1549-1676 |
DOI | 10.1371/journal.pmed.1001510 |
Cover
Loading…
Abstract | Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.
LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).
LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. |
---|---|
AbstractList | Please see later in the article for the Editors' Summary. Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/[mm.sup.3] or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries(57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96;95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users(IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19- 20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions:LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary. BackgroundFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.Methods and findingsLP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).ConclusionsLP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Background Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.BACKGROUNDFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).METHODS AND FINDINGSLP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.CONCLUSIONSLP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe. Please see later in the article for the Editors' Summary Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe. Please see later in the article for the Editors' Summary Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary Every year about 2.5 million people become newly infected with HIV, the virus that causes AIDS. HIV can be transmitted through unprotected sex with an infected partner, from an HIV-positive mother to her unborn baby, or through injection of drugs. Most people do not become ill immediately after infection with HIV although some develop a short influenza-like illness. The next stage of the HIV infection, which may last up to 10 years, also has no major symptoms but, during this stage, HIV slowly destroys immune system cells, including CD4 cells, a type of lymphocyte. Eventually, when the immune system is unable to fight off infections by other disease-causing organisms, HIV-positive people develop AIDS-defining conditions-unusual viral, bacterial, and fungal infections and unusual tumors. Progression to AIDS occurs when any severe AIDS-defining condition is diagnosed, when the CD4 count in the blood falls below 200 cells/mm3, or when CD4 cells account for fewer than 15% of lymphocytes. People need to know they are HIV positive as soon as possible after they become infected because antiretroviral therapy, which controls but does not cure HIV infection, works best if it is initiated when people still have a relatively high CD4 count. Early diagnosis also reduces the risk of onward HIV transmission. However, 40%-60% of HIV-positive individuals in developed countries are not diagnosed until they have a low CD4 count or an AIDS-defining illness. Reasons for such late presentation include fear of discrimination or stigmatization, limited knowledge about HIV risk factors, testing, and treatment together with missed opportunities to offer an HIV test. Policy makers involved in national and international HIV control programs need detailed information about patterns of late presentation before they can make informed decisions about how to reduce this problem. In this study, therefore, the researchers use data collected by the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) to analyze trends in late presentation over time across Europe and in different groups of people at risk of HIV infection and to investigate the clinical consequences of late presentation. The researchers analyzed data collected from 84,524 individuals participating in more than 20 observational studies that were undertaken in 35 European countries and that investigated outcomes among HIV-positive people. Nearly 54% of the participants were late presenters-individuals who had a CD4 count of less than 350 cells/mm3 or an AIDS-defining illness within 6 months of HIV diagnosis. Late presentation was highest among heterosexual males, in Southern European countries, and among people originating in Africa. Overall, late presentation decreased from 57.3% in 2000 to 51.7% in 2010/11. However, whereas late presentation decreased over time among men having sex with men in Central and Northern Europe, for example, it increased over time among female heterosexuals in Southern Europe. Finally, among the 8,000 individuals who developed a new AIDS-defining illness or died during follow-up, compared to non-late presentation, late presentation was associated with an increased incidence of AIDS/death in all regions of Europe during the first and second year after HIV diagnosis (but not in later years); the largest increase in incidence (13-fold) occurred during the first year after diagnosis in Southern Europe. These findings indicate that, although late presentation with HIV infection has decreased in recent years, it remains an important issue across Europe and in all... |
Audience | Academic |
Author | Reekie, Joanne Brockmeyer, Norbert Casabona, Jordi Torti, Carlo Reiss, Peter Skaletz-Rorowski, Adriane Johnson, Anne M. De Wit, Stéphane Castagna, Antonella Sabin, Miriam Lewis Fabre-Colin, Céline Leport, Catherine Lundgren, Jens D. Costagliola, Dominique Chene, Genevieve Sabin, Caroline Kjaer, Jesper Suarez-Lozano, Ignacio Mocroft, Amanda Furrer, Hansjakob Lazanas, Marios K. Fätkenheuer, Gerd Dabis, Francois Moreno, Santiago Monforte, Antonella d'Arminio Post, Frank A. Zangerle, Robert Warszawski, Josiane Obel, Niels Grarup, Jesper Kirk, Ole |
AuthorAffiliation | 19 Kings College London School of Medicine, London, United Kingdom 1 Department of Infection and Population Health, University College London, London, United Kingdom 5 Department of Dermatology, Venerology, and Allergology, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany 23 German Competence Network for HIV/AIDS, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany 29 Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France 25 University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, Brescia, Italy 10 Université of Bordeaux, ISPED, Centre Inserm, U897–Epidémiologie–Biostatistiques, Bordeaux, France 13 Universität Köln, Cologne, Germany 15 3rd Internal Medicine Department and Infectious Disease Unit, Red Cross General Hospital of Athens, Greece 30 INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France Centers for Disease Control and Prevention, United States of America 16 Unive |
AuthorAffiliation_xml | – name: 2 Copenhagen HIV programme, University of Copenhagen, Copenhagen, Denmark – name: 26 Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University “Magna Graecia,” Catanzaro, Italy – name: 5 Department of Dermatology, Venerology, and Allergology, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany – name: 11 Inserm U897–Epidémiologie–Biostatistiques, Bordeaux, France – name: 13 Universität Köln, Cologne, Germany – name: 10 Université of Bordeaux, ISPED, Centre Inserm, U897–Epidémiologie–Biostatistiques, Bordeaux, France – name: 16 Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France – name: Centers for Disease Control and Prevention, United States of America – name: 15 3rd Internal Medicine Department and Infectious Disease Unit, Red Cross General Hospital of Athens, Greece – name: 8 UPMC Université Paris 06, UMR_S 943, Paris, France – name: 20 The Kirby Institute, University of New South Wales, Sydney, Australia – name: 6 CEEISCAT (Agència de Salut Pública de Catalunya) and CIBERESP, Badalona, Catalonia, Spain – name: 19 Kings College London School of Medicine, London, United Kingdom – name: 14 Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland – name: 22 Stichting HIV Monitoring, Amsterdam, The Netherlands – name: 21 Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands – name: 27 INSERM CESP U1018, Université Paris-Sud, AP-HP Public Health Department, Le Kremlin-Bicêtre, France – name: 29 Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France – name: 28 Medical University Innsbruck, Innsbruck, Austria – name: 3 Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark – name: 25 University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, Brescia, Italy – name: 7 Department of Infectious Diseases IRCCS San Raffaele, Milan, Italy – name: 30 INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France – name: 1 Department of Infection and Population Health, University College London, London, United Kingdom – name: 23 German Competence Network for HIV/AIDS, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany – name: 18 Department of Infectious Diseases. University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain – name: 24 Infectious Diseases Unit, Complejo Hospitalario de Huelva, Spanish VACH Cohort, Spain – name: 12 Saint-Pierre Hospital, Brussels, Belgium – name: 4 Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy – name: 17 INSERM, UMR 738, Paris, France – name: 9 INSERM, UMR_S 943, Paris, France |
Author_xml | – sequence: 1 givenname: Amanda surname: Mocroft fullname: Mocroft, Amanda – sequence: 2 givenname: Jens D. surname: Lundgren fullname: Lundgren, Jens D. – sequence: 3 givenname: Miriam Lewis surname: Sabin fullname: Sabin, Miriam Lewis – sequence: 4 givenname: Antonella d'Arminio surname: Monforte fullname: Monforte, Antonella d'Arminio – sequence: 5 givenname: Norbert surname: Brockmeyer fullname: Brockmeyer, Norbert – sequence: 6 givenname: Jordi surname: Casabona fullname: Casabona, Jordi – sequence: 7 givenname: Antonella surname: Castagna fullname: Castagna, Antonella – sequence: 8 givenname: Dominique surname: Costagliola fullname: Costagliola, Dominique – sequence: 9 givenname: Francois surname: Dabis fullname: Dabis, Francois – sequence: 10 givenname: Stéphane surname: De Wit fullname: De Wit, Stéphane – sequence: 11 givenname: Gerd surname: Fätkenheuer fullname: Fätkenheuer, Gerd – sequence: 12 givenname: Hansjakob surname: Furrer fullname: Furrer, Hansjakob – sequence: 13 givenname: Anne M. surname: Johnson fullname: Johnson, Anne M. – sequence: 14 givenname: Marios K. surname: Lazanas fullname: Lazanas, Marios K. – sequence: 15 givenname: Catherine surname: Leport fullname: Leport, Catherine – sequence: 16 givenname: Santiago surname: Moreno fullname: Moreno, Santiago – sequence: 17 givenname: Niels surname: Obel fullname: Obel, Niels – sequence: 18 givenname: Frank A. surname: Post fullname: Post, Frank A. – sequence: 19 givenname: Joanne surname: Reekie fullname: Reekie, Joanne – sequence: 20 givenname: Peter surname: Reiss fullname: Reiss, Peter – sequence: 21 givenname: Caroline surname: Sabin fullname: Sabin, Caroline – sequence: 22 givenname: Adriane surname: Skaletz-Rorowski fullname: Skaletz-Rorowski, Adriane – sequence: 23 givenname: Ignacio surname: Suarez-Lozano fullname: Suarez-Lozano, Ignacio – sequence: 24 givenname: Carlo surname: Torti fullname: Torti, Carlo – sequence: 25 givenname: Josiane surname: Warszawski fullname: Warszawski, Josiane – sequence: 26 givenname: Robert surname: Zangerle fullname: Zangerle, Robert – sequence: 27 givenname: Céline surname: Fabre-Colin fullname: Fabre-Colin, Céline – sequence: 28 givenname: Jesper surname: Kjaer fullname: Kjaer, Jesper – sequence: 29 givenname: Genevieve surname: Chene fullname: Chene, Genevieve – sequence: 30 givenname: Jesper surname: Grarup fullname: Grarup, Jesper – sequence: 31 givenname: Ole surname: Kirk fullname: Kirk, Ole |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24137103$$D View this record in MEDLINE/PubMed |
BookMark | eNqVk91q2zAUgM3oWH-2NxiboDDai2SSJdlWLwYlpGugLCXdeitk-ThR51iZJJf1xfZ8k5t0NKOMDl_YPv7OJ_nonP1kp7UtJMlbgoeE5uTjje1cq5rhagnVkGBMOMEvkj3CmRiQLM92Hj3vJvve32CcCizwq2Q3Zb0C073k18z47-hM6WCdR6qt0LQL2i7Bo9o6dKECoEsHHtqggrHtffR8cj24tN4Ecxu_gvO29ci0aNw5u4ITNAPfNSEanF2isAA0sk2jSuvWClujaenB3d6_qqb3ofHKVLA0trFzo2MsOkA5vdhI0VXoqjt0NJqej2fj49fJy1o1Ht5s7gfJt7Px19H54GL6eTI6vRjoXPAwIJBWGTDNoNREp4qnLK1YoYCDEIQVtBZE8KJUBeelpmkNWV1ShTVTRZlWgh4k79feVWO93JTcS8JYSgXmRRaJyZqorLqRK2eWyt1Jq4y8D1g3l8oFoxuQBMosLwCnqsCMqVwoQuuMFwUmmdIlia5Pm9W6Mp6qjkV3qtmSbn9pzULO7a2kucgEy6PgaCNw9kcHPsil8Rpi8VuwXb9vXnBKMU2fgTIqRBSziB6u0bmKf2Ha2sbFdY_LU8pynqZc4EgNnqDm0ELcaWzd2sTwFj98go9X3wb6yYTjrYTIBPgZ5qrzXk6uZv_Bfnk-O73eZj88YhegmrDwtun6Rvbb4LvHR_nnDB8mLwIna0A7672DWmqzHrFYBtNIgmVPPvSc7MdcbsY8JrO_kh_8_0z7DSfrVl0 |
CitedBy_id | crossref_primary_10_1097_EDE_0000000000000324 crossref_primary_10_4103_0366_6999_238152 crossref_primary_10_1590_s1980_220x2018009703439 crossref_primary_10_1097_QAI_0000000000001153 crossref_primary_10_1111_hiv_13450 crossref_primary_10_1136_bmjopen_2016_012721 crossref_primary_10_7448_IAS_17_4_19856 crossref_primary_10_1080_14787210_2018_1545575 crossref_primary_10_1093_cid_ciy103 crossref_primary_10_3390_biom9060233 crossref_primary_10_7448_IAS_17_4_19619 crossref_primary_10_1093_jac_dkw103 crossref_primary_10_1371_journal_pone_0277534 crossref_primary_10_1371_journal_pone_0249864 crossref_primary_10_1111_hiv_13323 crossref_primary_10_1371_journal_pone_0283648 crossref_primary_10_1007_s10903_017_0681_6 crossref_primary_10_1097_MD_0000000000030400 crossref_primary_10_1111_hiv_13440 crossref_primary_10_1093_jac_dkae081 crossref_primary_10_1111_hiv_12474 crossref_primary_10_2807_1560_7917_ES2015_20_14_21088 crossref_primary_10_1111_hiv_13443 crossref_primary_10_4236_wja_2014_42031 crossref_primary_10_1016_j_eclinm_2022_101600 crossref_primary_10_3390_ijerph13030320 crossref_primary_10_1186_s12879_016_1462_x crossref_primary_10_3390_pathogens10070835 crossref_primary_10_1007_s15010_015_0745_2 crossref_primary_10_1186_s12879_017_2398_5 crossref_primary_10_2807_1560_7917_ES2015_20_14_21086 crossref_primary_10_1186_s12889_024_18499_6 crossref_primary_10_1186_s12879_017_2280_5 crossref_primary_10_1016_S2352_3018_15_00006_5 crossref_primary_10_1038_s41385_018_0083_7 crossref_primary_10_1097_CCM_0000000000001385 crossref_primary_10_1186_s12879_020_05261_7 crossref_primary_10_1186_s12879_019_4156_3 crossref_primary_10_1097_QAD_0000000000003683 crossref_primary_10_1007_s15010_016_0887_x crossref_primary_10_1080_09540121_2018_1470306 crossref_primary_10_1111_hiv_12347 crossref_primary_10_1111_hiv_13436 crossref_primary_10_3851_IMP2990 crossref_primary_10_1080_09540121_2021_1884181 crossref_primary_10_1136_sextrans_2020_054697 crossref_primary_10_2196_resprot_5162 crossref_primary_10_58395_pipd_v50i1_80 crossref_primary_10_1093_cid_ciw065 crossref_primary_10_1097_QAI_0000000000001939 crossref_primary_10_1097_QAI_0000000000001498 crossref_primary_10_1093_eurpub_ckx225 crossref_primary_10_1080_09540121_2019_1612021 crossref_primary_10_1016_j_jinf_2016_01_017 crossref_primary_10_1186_s12889_015_2571_y crossref_primary_10_3390_tropicalmed9090213 crossref_primary_10_1007_s11904_014_0202_3 crossref_primary_10_1371_journal_pone_0214739 crossref_primary_10_1111_1471_0528_14614 crossref_primary_10_1371_journal_pone_0176914 crossref_primary_10_5694_mja2_50006 crossref_primary_10_1097_COH_0000000000000307 crossref_primary_10_5114_amscd_2016_63157 crossref_primary_10_1097_QAI_0000000000000717 crossref_primary_10_1007_s12250_018_0028_z crossref_primary_10_1080_09540121_2023_2185196 crossref_primary_10_1155_2023_9488051 crossref_primary_10_2807_1560_7917_ES_2024_29_48_2400759 crossref_primary_10_1007_s15010_014_0646_9 crossref_primary_10_1097_COH_0000000000000076 crossref_primary_10_1371_journal_pone_0162503 crossref_primary_10_1089_apc_2020_0044 crossref_primary_10_1093_cid_cix858 crossref_primary_10_1007_s11904_014_0198_8 crossref_primary_10_1017_S0022215119002019 crossref_primary_10_1371_journal_pone_0142576 crossref_primary_10_1016_j_antiviral_2019_104577 crossref_primary_10_1186_s12981_021_00415_2 crossref_primary_10_1186_s12889_018_5500_z crossref_primary_10_1586_14787210_2015_1029917 crossref_primary_10_1080_09540121_2014_906554 crossref_primary_10_1097_QAD_0000000000000524 crossref_primary_10_1097_QAI_0000000000000825 crossref_primary_10_1002_jmv_28781 crossref_primary_10_1007_s15010_018_1167_8 crossref_primary_10_1093_eurpub_ckx048 crossref_primary_10_1111_hiv_13121 crossref_primary_10_1371_journal_pone_0140845 crossref_primary_10_1016_j_maturitas_2017_11_012 crossref_primary_10_1016_j_maturitas_2016_03_015 crossref_primary_10_3390_jcm10040716 crossref_primary_10_1186_s12916_017_0856_y crossref_primary_10_1586_14787210_2016_1106937 crossref_primary_10_1016_S2352_3018_15_00252_0 crossref_primary_10_1038_s41598_021_01885_0 crossref_primary_10_1371_journal_pone_0162739 crossref_primary_10_2196_11136 crossref_primary_10_1007_s10903_016_0385_3 crossref_primary_10_1089_apc_2015_0094 crossref_primary_10_1186_s12981_016_0129_4 crossref_primary_10_1371_journal_pone_0207355 crossref_primary_10_1371_journal_pone_0143320 crossref_primary_10_7448_IAS_18_1_20024 crossref_primary_10_1097_QAD_0000000000000530 crossref_primary_10_1097_QAD_0000000000000410 crossref_primary_10_1097_QAI_0000000000001585 crossref_primary_10_1371_journal_pone_0188751 crossref_primary_10_3389_fimmu_2017_01189 crossref_primary_10_1371_journal_pone_0259073 crossref_primary_10_4103_jfmpc_jfmpc_414_21 crossref_primary_10_1186_s12879_018_3661_0 crossref_primary_10_1089_aid_2020_0175 crossref_primary_10_1007_s40121_021_00494_8 crossref_primary_10_1371_journal_pone_0118492 crossref_primary_10_1017_S0950268823000043 crossref_primary_10_1111_hiv_12735 crossref_primary_10_3389_fpubh_2023_1193236 crossref_primary_10_51523_2708_6011_2019_16_4_3 crossref_primary_10_1016_j_puhe_2016_10_009 crossref_primary_10_1111_hiv_12175 crossref_primary_10_3851_IMP2960 crossref_primary_10_1016_j_eclinm_2021_100877 crossref_primary_10_1089_apc_2016_0082 crossref_primary_10_1002_jia2_25726 crossref_primary_10_1186_s12981_019_0221_7 crossref_primary_10_1371_journal_pone_0214421 crossref_primary_10_2989_16085906_2018_1490785 crossref_primary_10_1089_aid_2014_0205 crossref_primary_10_1093_ije_dyw211 crossref_primary_10_1111_hiv_12727 crossref_primary_10_2807_1560_7917_ES_2015_20_47_30070 crossref_primary_10_1093_ve_vew010 crossref_primary_10_1007_s00103_016_2320_0 crossref_primary_10_1111_hiv_12962 crossref_primary_10_1016_j_lpm_2017_11_022 crossref_primary_10_1080_09540121_2016_1224306 crossref_primary_10_1186_1471_2334_14_S6_S18 crossref_primary_10_1093_cid_ciu1138 crossref_primary_10_1111_tmi_12746 crossref_primary_10_1310_hct1504_133 crossref_primary_10_2807_1560_7917_ES2014_19_47_20968 crossref_primary_10_1177_0956462418796445 crossref_primary_10_1089_aid_2015_0058 crossref_primary_10_2807_1560_7917_ES2013_18_48_20647 crossref_primary_10_1186_s12889_016_3477_z crossref_primary_10_2217_fvl_15_66 crossref_primary_10_1136_sextrans_2014_051980 crossref_primary_10_1097_QAD_0000000000001411 crossref_primary_10_1371_journal_pone_0180361 crossref_primary_10_1136_bmjopen_2017_019806 crossref_primary_10_2807_1560_7917_ES_2019_24_41_1900225 crossref_primary_10_1371_journal_pone_0220108 crossref_primary_10_1007_s15010_014_0719_9 crossref_primary_10_1111_hiv_13041 crossref_primary_10_1186_s12981_015_0079_2 crossref_primary_10_2807_1560_7917_ES2014_19_47_20973 crossref_primary_10_1093_ofid_ofac611 crossref_primary_10_1186_s12879_015_0940_x crossref_primary_10_3390_jcm8020163 crossref_primary_10_1097_MD_0000000000014664 crossref_primary_10_1155_2016_1631878 crossref_primary_10_1371_journal_pone_0284688 crossref_primary_10_2807_1560_7917_ES_2022_27_30_2100809 crossref_primary_10_1371_journal_pone_0145380 crossref_primary_10_1007_s13365_014_0266_2 crossref_primary_10_1371_journal_pone_0182335 crossref_primary_10_1080_09540121_2014_938016 crossref_primary_10_1177_0956462416649327 crossref_primary_10_1016_j_hlpt_2017_01_005 crossref_primary_10_1093_cid_ciy400 crossref_primary_10_7448_IAS_18_1_19463 crossref_primary_10_1371_journal_pone_0156360 crossref_primary_10_1097_QAI_0000000000000567 crossref_primary_10_3389_fmed_2023_1182359 crossref_primary_10_1080_09540121_2019_1576842 crossref_primary_10_1177_0956462415623402 crossref_primary_10_1097_QAD_0000000000000222 crossref_primary_10_1097_QAI_0000000000003398 crossref_primary_10_1016_j_ejim_2019_09_006 crossref_primary_10_1007_s10903_018_0834_2 crossref_primary_10_1016_j_cmi_2021_07_036 crossref_primary_10_1186_s12879_018_3251_1 crossref_primary_10_7448_IAS_18_1_20317 crossref_primary_10_1093_cid_ciy414 crossref_primary_10_1186_s12889_018_6107_0 crossref_primary_10_1111_hiv_12403 crossref_primary_10_1371_journal_pone_0218380 crossref_primary_10_1097_QAD_0000000000002891 crossref_primary_10_1111_hiv_12762 crossref_primary_10_3390_pathogens13080683 crossref_primary_10_1111_hiv_12321 crossref_primary_10_1186_s12879_018_3573_z crossref_primary_10_1186_s12879_021_06183_8 crossref_primary_10_1371_journal_pone_0186835 crossref_primary_10_1007_s10461_018_2335_7 crossref_primary_10_1093_cid_cix212 crossref_primary_10_1097_MCG_0000000000001189 crossref_primary_10_1111_1753_6405_12910 crossref_primary_10_1093_cid_ciz877 crossref_primary_10_1186_s12879_022_07352_z crossref_primary_10_3390_pharmacy8020092 crossref_primary_10_1002_jia2_26086 crossref_primary_10_1371_journal_pmed_1002479 crossref_primary_10_1097_QAD_0000000000000243 crossref_primary_10_1186_s13011_022_00439_5 crossref_primary_10_1111_hiv_13407 crossref_primary_10_1016_j_ijid_2018_03_007 crossref_primary_10_1016_j_ijid_2024_106995 crossref_primary_10_1097_COH_0000000000000241 crossref_primary_10_1111_hiv_12430 crossref_primary_10_1093_infdis_jiaa669 crossref_primary_10_1371_journal_pone_0113062 crossref_primary_10_1590_S1518_8787_2016050006352 crossref_primary_10_1371_journal_pone_0124741 crossref_primary_10_1186_s40249_016_0193_y crossref_primary_10_1093_jac_dkab168 crossref_primary_10_1002_hed_25421 crossref_primary_10_1186_s12879_018_2971_6 crossref_primary_10_1111_hiv_12545 crossref_primary_10_1093_cid_cix915 crossref_primary_10_1111_hiv_12101 crossref_primary_10_1093_jac_dkv272 crossref_primary_10_2807_1560_7917_ES_2020_25_47_2001943 crossref_primary_10_1371_journal_pone_0197990 crossref_primary_10_1093_cid_civ732 crossref_primary_10_1002_jmv_28288 crossref_primary_10_1007_s15006_014_3119_2 crossref_primary_10_1097_QAD_0000000000003658 crossref_primary_10_1136_postgradmedj_2019_137093 crossref_primary_10_1038_s41598_023_50713_0 crossref_primary_10_1111_hiv_13426 crossref_primary_10_1016_S2352_3018_24_00212_1 crossref_primary_10_1097_MD_0000000000026507 crossref_primary_10_1186_s12879_018_3249_8 crossref_primary_10_1186_s12889_021_10421_8 crossref_primary_10_23950_jcmk_15488 crossref_primary_10_1371_journal_pone_0133232 crossref_primary_10_1093_cid_cix927 crossref_primary_10_1177_0956462416650980 crossref_primary_10_1136_bmjopen_2015_009688 crossref_primary_10_2196_14145 crossref_primary_10_1016_j_ijantimicag_2023_107018 crossref_primary_10_1016_j_medcli_2023_12_007 crossref_primary_10_1016_j_ijantimicag_2023_107016 crossref_primary_10_1016_j_medcle_2023_12_010 crossref_primary_10_1097_QAD_0000000000001126 crossref_primary_10_1016_j_parint_2024_102983 crossref_primary_10_1111_hiv_12686 crossref_primary_10_3389_fphar_2021_773848 |
Cites_doi | 10.1186/1471-2458-13-281 10.1097/01.qai.0000286597.57066.2b 10.1186/1471-2334-11-11 10.1097/QAD.0b013e32801138f7 10.1001/archinte.160.17.2614 10.3109/00365548.2011.626440 10.1371/journal.pone.0041673 10.1093/eurpub/ckm117 10.3851/IMP1883 10.1097/QAD.0b013e32833f9e1d 10.3851/IMP1526 10.1016/S0140-6736(10)60232-2 10.1177/135965350701200111 10.1111/j.1468-1293.2011.00959.x 10.1097/00002030-200209270-00012 10.1097/00002030-199807000-00016 10.1097/00002030-200411050-00006 10.1177/135965350400900421 10.1056/NEJM200003303421303 10.1093/eurpub/ckp231 10.1097/MLR.0b013e3181f81c4a 10.3851/IMP1522 10.1111/j.1468-1293.2011.00958.x 10.1258/ijsa.2011.011280 10.1186/1742-6405-8-22 10.1111/j.1468-1293.2010.00857.x 10.1097/00126334-200408010-00009 10.1136/bmjopen-2012-001465 10.2807/ese.16.48.20030-en 10.1177/135965350701200612 10.1001/archinte.158.7.734 10.1371/journal.pone.0052845 |
ContentType | Journal Article |
Contributor | Reekie, Joanne Battegay, Manuel Reiss, Peter Skaletz-Rorowski, Adriane Touloumi, Giota Del Amo, Julia Ramos, José Costagliola, Dominique Gibb, Diana Sabin, Miriam Sabin, Caroline Thorne, Claire Kjaer, Jesper Krause, Murielle Mary Mocroft, Amanda Furrer, Hansjakob Fätkenheuer, Gerd Teira, Ramon Lundgren, Jens Dabis, Francois de Wit, Stephane Moreno, Santiago Zangerle, Robert Obel, Niels Grarup, Jesper Pérez-Hoyos, Santiago Tookey, Pat Kirk, Ole Mussini, Cristina de Wolf, Frank Lazanas, Mario Brockmeyer, Norbert Casabona, Jordi Torti, Carlo Monforte, Antonella d' Arminio Schwimmer, Christine Ghosn, Jade De Wit, Stéphane Castagna, Antonella Noguera-Julian, Antoni Antinori, Andrea Fabre-Colin, Céline Leport, Catherine Chene, Genevieve Johnson, Hansjakob Furrer Anne Suarez-Loano, Ignacio Johnson, Anne Hamouda, Osamah Garrido, Myriam Bucher, Heiner Bartmeyer, Barbara Miro, Jose M Meyer, Laurence Rauch, Andri Haerry, David Post, Frank Goetghebuer, Tessa Weller, Ian Stephan, Christoph Termote, Monique Dabis, François Prins, Maria Warszawski, Josiane Judd, |
Contributor_xml | – sequence: 1 givenname: Amanda surname: Mocroft fullname: Mocroft, Amanda – sequence: 2 givenname: Jens surname: Lundgren fullname: Lundgren, Jens – sequence: 3 givenname: Miriam surname: Sabin fullname: Sabin, Miriam – sequence: 4 givenname: Norbert surname: Brockmeyer fullname: Brockmeyer, Norbert – sequence: 5 givenname: Jordi surname: Casabona fullname: Casabona, Jordi – sequence: 6 givenname: Antonella surname: Castagna fullname: Castagna, Antonella – sequence: 7 givenname: Dominique surname: Costagliola fullname: Costagliola, Dominique – sequence: 8 givenname: Francois surname: Dabis fullname: Dabis, Francois – sequence: 9 givenname: Stéphane surname: De Wit fullname: De Wit, Stéphane – sequence: 10 givenname: Gerd surname: Fätkenheuer fullname: Fätkenheuer, Gerd – sequence: 11 givenname: Hansjakob surname: Furrer fullname: Furrer, Hansjakob – sequence: 12 givenname: Anne surname: Johnson fullname: Johnson, Anne – sequence: 13 givenname: Mario surname: Lazanas fullname: Lazanas, Mario – sequence: 14 givenname: Catherine surname: Leport fullname: Leport, Catherine – sequence: 15 givenname: Santiago surname: Moreno fullname: Moreno, Santiago – sequence: 16 givenname: Niels surname: Obel fullname: Obel, Niels – sequence: 17 givenname: Frank surname: Post fullname: Post, Frank – sequence: 18 givenname: Joanne surname: Reekie fullname: Reekie, Joanne – sequence: 19 givenname: Peter surname: Reiss fullname: Reiss, Peter – sequence: 20 givenname: Caroline surname: Sabin fullname: Sabin, Caroline – sequence: 21 givenname: Adriane surname: Skaletz-Rorowski fullname: Skaletz-Rorowski, Adriane – sequence: 22 givenname: Ignacio surname: Suarez-Loano fullname: Suarez-Loano, Ignacio – sequence: 23 givenname: Josiane surname: Warszawski fullname: Warszawski, Josiane – sequence: 24 givenname: Robert surname: Zangerle fullname: Zangerle, Robert – sequence: 25 givenname: Jesper surname: Kjaer fullname: Kjaer, Jesper – sequence: 26 givenname: Genevieve surname: Chene fullname: Chene, Genevieve – sequence: 27 givenname: Jesper surname: Grarup fullname: Grarup, Jesper – sequence: 28 givenname: Ole surname: Kirk fullname: Kirk, Ole – sequence: 29 givenname: Hansjakob Furrer Anne surname: Johnson fullname: Johnson, Hansjakob Furrer Anne – sequence: 30 givenname: Carlo surname: Torti fullname: Torti, Carlo – sequence: 31 givenname: Giota surname: Touloumi fullname: Touloumi, Giota – sequence: 32 givenname: Laurence surname: Meyer fullname: Meyer, Laurence – sequence: 33 givenname: François surname: Dabis fullname: Dabis, François – sequence: 34 givenname: Murielle Mary surname: Krause fullname: Krause, Murielle Mary – sequence: 35 givenname: Jade surname: Ghosn fullname: Ghosn, Jade – sequence: 36 givenname: Frank surname: de Wolf fullname: de Wolf, Frank – sequence: 37 givenname: Maria surname: Prins fullname: Prins, Maria – sequence: 38 givenname: Heiner surname: Bucher fullname: Bucher, Heiner – sequence: 39 givenname: Diana surname: Gibb fullname: Gibb, Diana – sequence: 40 givenname: Osamah surname: Hamouda fullname: Hamouda, Osamah – sequence: 41 givenname: Barbara surname: Bartmeyer fullname: Bartmeyer, Barbara – sequence: 42 givenname: Julia surname: Del Amo fullname: Del Amo, Julia – sequence: 43 givenname: Claire surname: Thorne fullname: Thorne, Claire – sequence: 44 givenname: Christoph surname: Stephan fullname: Stephan, Christoph – sequence: 45 givenname: Santiago surname: Pérez-Hoyos fullname: Pérez-Hoyos, Santiago – sequence: 46 givenname: Antoni surname: Noguera-Julian fullname: Noguera-Julian, Antoni – sequence: 47 givenname: Andrea surname: Antinori fullname: Antinori, Andrea – sequence: 48 givenname: Antonella d' Arminio surname: Monforte fullname: Monforte, Antonella d' Arminio – sequence: 49 givenname: José surname: Ramos fullname: Ramos, José – sequence: 50 givenname: Manuel surname: Battegay fullname: Battegay, Manuel – sequence: 51 givenname: Andri surname: Rauch fullname: Rauch, Andri – sequence: 52 givenname: Cristina surname: Mussini fullname: Mussini, Cristina – sequence: 53 givenname: Pat surname: Tookey fullname: Tookey, Pat – sequence: 54 givenname: Jose M surname: Miro fullname: Miro, Jose M – sequence: 55 givenname: Stephane surname: de Wit fullname: de Wit, Stephane – sequence: 56 givenname: Tessa surname: Goetghebuer fullname: Goetghebuer, Tessa – sequence: 57 givenname: Ramon surname: Teira fullname: Teira, Ramon – sequence: 58 givenname: Myriam surname: Garrido fullname: Garrido, Myriam – sequence: 59 givenname: Ali surname: Judd fullname: Judd, Ali – sequence: 60 givenname: David surname: Haerry fullname: Haerry, David – sequence: 61 givenname: Ian surname: Weller fullname: Weller, Ian – sequence: 62 givenname: Céline surname: Fabre-Colin fullname: Fabre-Colin, Céline – sequence: 63 givenname: Christine surname: Schwimmer fullname: Schwimmer, Christine – sequence: 64 givenname: Monique surname: Termote fullname: Termote, Monique |
Copyright | COPYRIGHT 2013 Public Library of Science 2013 Mocroft et al 2013 Mocroft et al 2013 Mocroft et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, et al. (2013) Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 10(9): e1001510. doi:10.1371/journal.pmed.1001510 |
Copyright_xml | – notice: COPYRIGHT 2013 Public Library of Science – notice: 2013 Mocroft et al 2013 Mocroft et al – notice: 2013 Mocroft et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, et al. (2013) Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 10(9): e1001510. doi:10.1371/journal.pmed.1001510 |
CorporateAuthor | Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord |
CorporateAuthor_xml | – name: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISN ISR 7X8 7U1 C1K 5PM DOA CZK |
DOI | 10.1371/journal.pmed.1001510 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science MEDLINE - Academic Risk Abstracts Environmental Sciences and Pollution Management PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals PLoS Medicine |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Risk Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE MEDLINE - Academic Risk Abstracts |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Late Presentation of HIV Infection across Europe |
EISSN | 1549-1676 |
ExternalDocumentID | 1442390586 oai_doaj_org_article_1eb678e02a8044a79a13f6588016acb1 PMC3796947 A347522590 24137103 10_1371_journal_pmed_1001510 |
Genre | Research Support, Non-U.S. Gov't Journal Article Observational Study |
GeographicLocations | Europe United States Africa |
GeographicLocations_xml | – name: Europe – name: United States – name: Africa |
GrantInformation_xml | – fundername: Medical Research Council grantid: G0900274 |
GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAUCC AAWOE AAWTL AAYXX ABDBF ABUWG ACGFO ACIHN ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAWUL BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IOF IOV IPO ISN ISR ITC KQ8 M1P M48 MK0 O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RNS RPM SV3 TR2 TUS UKHRP WOW XSB YZZ ~8M ADXHL CGR CUY CVF ECM EIF H13 IPNFZ NPM PJZUB PPXIY PV9 RIG RZL WOQ PMFND 7X8 7U1 C1K 5PM PUEGO 3V. AAPBV ABPTK BCGST CZK ICW M~E |
ID | FETCH-LOGICAL-c795t-1e2d6e4c4ebc1c2a5242d48ae5e991483f91958ba855bc32fe6fb3a0c4a8b2d93 |
IEDL.DBID | M48 |
ISSN | 1549-1676 1549-1277 |
IngestDate | Sun Oct 01 00:20:28 EDT 2023 Wed Aug 27 01:26:03 EDT 2025 Thu Aug 21 13:54:03 EDT 2025 Fri Jul 11 05:34:29 EDT 2025 Mon Jul 21 11:25:24 EDT 2025 Tue Jun 17 21:56:09 EDT 2025 Thu Jun 12 23:40:33 EDT 2025 Tue Jun 10 20:33:10 EDT 2025 Fri Jun 27 03:41:45 EDT 2025 Fri Jun 27 05:04:27 EDT 2025 Fri Jun 27 03:34:43 EDT 2025 Thu May 22 21:19:38 EDT 2025 Mon Jul 21 05:54:39 EDT 2025 Tue Jul 01 01:44:28 EDT 2025 Thu Apr 24 23:06:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | HIV Infections HIV Seropositivity Sensitivity & Specificity Europe Humans Risk Factors Cooperative Behavior Male Treatment Outcome CD4 Lymphocyte Count Substance Abuse, Intravenous Disease Progression Incidence Time Factors Female |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c795t-1e2d6e4c4ebc1c2a5242d48ae5e991483f91958ba855bc32fe6fb3a0c4a8b2d93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Conceived and designed the experiments: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Analyzed the data: AM JR. Wrote the first draft of the manuscript: AM. Contributed to the writing of the manuscript: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. ICMJE criteria for authorship read and met: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Agree with manuscript results and conclusions: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Enrolled patients: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. AM has received lecture fees, honoraria, and/or consultancies from Pfizer, BI, BMS, Merck, and Gilead. Ad'A is an advisory board member of BMS, Jannsen, Gilead, and ViiV. GF has received honoraria for lectures and advisory boards from Abbott, Bristol-Myers Squibb, Gilead, Janssen-Cilag, and Merck Sharp & Dohme. Research grant to GF from the German Federal Ministry of Education and Research (BMBF) 01KI1017. AJ is a Governor of the Wellcome Trust, a charitable research funding body; in 2011 was a specialist adviser to House of Lords Select Committee on HIV/AIDS; is a member of the UK Expert Advisory Group on AIDS; receives research grant funding from the UK Medical Research Council, Wellcome Trust, UK National Institute for Health Research, and Department of Health. CL has received these research grants: ANRS CMIT soutien (Aproco-Copilote ANRS CO08 HIV cohort, 1997–2012); IMMI (Cohort Fluco A(H1N1) pandemic influenza, 2009–2012); Ministère de la Santé PHRC (Bivir influenza trial, Oseltamivir Zanamivir, 2006–2012). CS has received funding for Advisory Board membership, speaker panels, and provision of educational materials for Gilead Sciences, Abbott Pharmaceuticals, ViiV, Merck Sharp & Dohme, Janssen-Cilag, and Bristol-Myers Squibb. CT has received honoraria to act as speaker at CME conferences on antiretroviral therapy and HIV disease management from several companies producing antiretroviral drugs, received travel grants to participate in scientific conferences, and acted as scientific consultant for the same companies. GC has had scientific responsibilities in projects receiving specific grant support from the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the European Commission (Framework Program 7), UK Medical Research Council, US National Institute of Health (NIH), Fondation Plan Alzheimer, Gilead, Tibotec, Boehringer Ingelheim, GlaxoSmithKline, Roche, Pfizer, Merck, Abbott, Bristol-Myers Squibb, Janssen, ViiV Healthcare – these grants are managed through her Institution or a non-profit society. GC also serves as Academic Editor on PLOS ONE and is on the editorial board of the BMC Infectious Diseases Journal. OK has received honoraria, consultancy, lecture fees, and travel grants from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche, and ViiV Healthcare, and has served/is serving on Advisory Boards for Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. No other competing interests have been declared. Membership of the Late Presenters Working Group and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study is provided in the Acknowledgments. |
OpenAccessLink | https://doaj.org/article/1eb678e02a8044a79a13f6588016acb1 |
PMID | 24137103 |
PQID | 1443993794 |
PQPubID | 23479 |
ParticipantIDs | plos_journals_1442390586 doaj_primary_oai_doaj_org_article_1eb678e02a8044a79a13f6588016acb1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3796947 proquest_miscellaneous_1458533032 proquest_miscellaneous_1443993794 gale_infotracmisc_A347522590 gale_infotracgeneralonefile_A347522590 gale_infotracacademiconefile_A347522590 gale_incontextgauss_ISR_A347522590 gale_incontextgauss_ISN_A347522590 gale_incontextgauss_IOV_A347522590 gale_healthsolutions_A347522590 pubmed_primary_24137103 crossref_citationtrail_10_1371_journal_pmed_1001510 crossref_primary_10_1371_journal_pmed_1001510 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-09-01 |
PublicationDateYYYYMMDD | 2013-09-01 |
PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: San Francisco, USA |
PublicationTitle | PLoS medicine |
PublicationTitleAlternate | PLoS Med |
PublicationYear | 2013 |
Publisher | Public Library of Science Public Library of Science (PLoS) |
Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
References | ref35 ref34 TC Quinn (ref7) 2000; 342 BJ Turner (ref37) 2000; 160 N Dickson (ref26) 2012; 13 A Antinori (ref2) 2011; 12 CA Sabin (ref5) 2004; 18 M Battegay (ref4) 2007; 12 E Lanoy (ref6) 2007; 12 MA d'Arminio (ref15) 2011; 16 Y Yazdanpanah (ref12) 2010; 15 Suppl 1 L Camoni (ref16) 2013; 13 E Girardi (ref32) 2007; 46 Suppl 1 JH Samet (ref29) 1998; 158 A Zoufaly (ref14) 2012; 13 TR Chadborn (ref28) 2006; 20 B Ndiaye (ref19) 2011; 11 M Johnson (ref36) 2010; 15 Suppl 1 BM Mathers (ref25) 2010; 375 J Deblonde (ref11) 2010; 20 C Delpierre (ref30) 2008; 18 N Vives (ref17) 2012; 23 J Reekie (ref31) 2012; 7 PG de Olalla (ref22) 2011; 8 J Kjaer (ref13) 2004; 9 ref20 JA Fleishman (ref10) 2010; 48 ref21 M Helleberg (ref18) 2012; 44 J Castilla (ref23) 2002; 16 AK Sullivan (ref27) 2013; 8 ref8 E Jolley (ref33) 2012; 2 ref3 E Girardi (ref1) 2004; 36 HB Krentz (ref9) 2010; 24 E Couturier (ref24) 1998; 12 |
References_xml | – volume: 13 start-page: 281 year: 2013 ident: ref16 article-title: Late presenters among persons with a new HIV diagnosis in Italy, 2010–2011 publication-title: BMC Public Health doi: 10.1186/1471-2458-13-281 – volume: 46 Suppl 1 start-page: S3 year: 2007 ident: ref32 article-title: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000286597.57066.2b – ident: ref3 – volume: 11 start-page: 11 year: 2011 ident: ref19 article-title: Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997–2007 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-11-11 – volume: 20 start-page: 2371 year: 2006 ident: ref28 article-title: The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004) publication-title: AIDS doi: 10.1097/QAD.0b013e32801138f7 – volume: 160 start-page: 2614 year: 2000 ident: ref37 article-title: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus publication-title: Arch Intern Med doi: 10.1001/archinte.160.17.2614 – ident: ref20 – volume: 44 start-page: 282 year: 2012 ident: ref18 article-title: Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort publication-title: Scand J Infect Dis doi: 10.3109/00365548.2011.626440 – volume: 7 start-page: e41673 year: 2012 ident: ref31 article-title: Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study publication-title: PLoS One doi: 10.1371/journal.pone.0041673 – volume: 18 start-page: 345 year: 2008 ident: ref30 article-title: Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people publication-title: Eur J Public Health doi: 10.1093/eurpub/ckm117 – volume: 16 start-page: 1103 year: 2011 ident: ref15 article-title: Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome publication-title: Antivir Ther doi: 10.3851/IMP1883 – volume: 24 start-page: 2750 year: 2010 ident: ref9 article-title: Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 mul publication-title: AIDS doi: 10.1097/QAD.0b013e32833f9e1d – volume: 15 Suppl 1 start-page: 17 year: 2010 ident: ref12 article-title: Earlier testing for HIV–how do we prevent late presentation? publication-title: Antivir Ther doi: 10.3851/IMP1526 – volume: 375 start-page: 1014 year: 2010 ident: ref25 article-title: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage publication-title: Lancet doi: 10.1016/S0140-6736(10)60232-2 – volume: 12 start-page: 89 year: 2007 ident: ref6 article-title: Frequency, determinants and consequences of delayed access to care for HIV infection in France publication-title: Antivir Ther doi: 10.1177/135965350701200111 – volume: 13 start-page: 182 year: 2012 ident: ref26 article-title: Late presentation of HIV infection among adults in New Zealand: 2005–2010 publication-title: HIV Med doi: 10.1111/j.1468-1293.2011.00959.x – volume: 16 start-page: 1945 year: 2002 ident: ref23 article-title: Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence publication-title: AIDS doi: 10.1097/00002030-200209270-00012 – volume: 12 start-page: 795 year: 1998 ident: ref24 article-title: Determinants of delayed diagnosis of HIV infection in France, 1993–1995 publication-title: AIDS doi: 10.1097/00002030-199807000-00016 – volume: 18 start-page: 2145 year: 2004 ident: ref5 article-title: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy publication-title: AIDS doi: 10.1097/00002030-200411050-00006 – volume: 9 start-page: 631 year: 2004 ident: ref13 article-title: HIV cohort collaborations: proposal for harmonization of data exchange publication-title: Antivir Ther doi: 10.1177/135965350400900421 – volume: 342 start-page: 921 year: 2000 ident: ref7 article-title: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group publication-title: N Engl J Med doi: 10.1056/NEJM200003303421303 – volume: 20 start-page: 422 year: 2010 ident: ref11 article-title: Barriers to HIV testing in Europe: a systematic review publication-title: Eur J Public Health doi: 10.1093/eurpub/ckp231 – ident: ref21 – volume: 48 start-page: 1071 year: 2010 ident: ref10 article-title: The economic burden of late entry into medical care for patients with HIV infection publication-title: Med Care doi: 10.1097/MLR.0b013e3181f81c4a – volume: 15 Suppl 1 start-page: 3 year: 2010 ident: ref36 article-title: Definition and epidemiology of late presentation in Europe publication-title: Antivir Ther doi: 10.3851/IMP1522 – volume: 13 start-page: 172 year: 2012 ident: ref14 article-title: Late presentation for HIV diagnosis and care in Germany publication-title: HIV Med doi: 10.1111/j.1468-1293.2011.00958.x – volume: 23 start-page: 475 year: 2012 ident: ref17 article-title: Factors associated with late presentation of HIV infection in Catalonia, Spain publication-title: Int J STD AIDS doi: 10.1258/ijsa.2011.011280 – volume: 8 start-page: 22 year: 2011 ident: ref22 article-title: Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001–2009 publication-title: AIDS Res Ther doi: 10.1186/1742-6405-8-22 – ident: ref8 – volume: 12 start-page: 61 year: 2011 ident: ref2 article-title: Late presentation of HIV infection: a consensus definition publication-title: HIV Med doi: 10.1111/j.1468-1293.2010.00857.x – volume: 36 start-page: 951 year: 2004 ident: ref1 article-title: Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200408010-00009 – volume: 2 year: 2012 ident: ref33 article-title: HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy publication-title: BMJ Open doi: 10.1136/bmjopen-2012-001465 – ident: ref34 doi: 10.2807/ese.16.48.20030-en – volume: 12 start-page: 841 year: 2007 ident: ref4 article-title: Late presentation of HIV-infected individuals publication-title: Antivir Ther doi: 10.1177/135965350701200612 – ident: ref35 – volume: 158 start-page: 734 year: 1998 ident: ref29 article-title: Trillion virion delay: time from testing positive for HIV to presentation for primary care publication-title: Arch Intern Med doi: 10.1001/archinte.158.7.734 – volume: 8 start-page: e52845 year: 2013 ident: ref27 article-title: Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV Indicator Diseases across Europe Study) publication-title: PLoS One doi: 10.1371/journal.pone.0052845 |
SSID | ssj0029090 |
Score | 2.5495183 |
Snippet | Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the... Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to... Please see later in the article for the Editors' Summary. Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe.... BackgroundFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to... Background Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to... |
SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | e1001510 |
SubjectTerms | Acquired immune deficiency syndrome AIDS Care and treatment CD4 Lymphocyte Count Collaboration Cooperative Behavior Disease Progression Europe - epidemiology Female HIV HIV infection HIV Infections - diagnosis HIV Infections - epidemiology HIV Infections - immunology HIV patients HIV Seropositivity - epidemiology Host-parasite relationships Human immunodeficiency virus Humans Illnesses Immune system Incidence Infections Male Medical tests Medicine Mortality Patient outcomes Risk Factors Sensitivity and Specificity Studies Substance Abuse, Intravenous - epidemiology Time Factors Treatment Outcome |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZQHxAviPsyNjAIcXkIS2LnxtuoOnVIW6XCpr1FtmOPii6plhaJP8bv4xzHzRo0sT3w0ofki9v6HB9_jo-_Q8gb8IEkzYXxVShSH3cCfZiEpc9UDATfBGFpk2iOjpPxCf9yFp9tlPrCnLBWHrjtuL1QS4inOohEFnAuoN2QGZg2IbImQkm78IE5b72YckutPLBvV1B_zA-jNHWH5lga7jkbfVzAbGMViGI8PbsxKVnt_i5CDxbzurmOfv6dRbkxLR08IPcdn6T77f94SO7o6hG5e-R2zB-T39NZ84O6qjpUVCWtV0vwMt1QoKt0DlSTLq6OIFX26vjw1G-zuX7CXcvJGzqraPvq_hMF_Gq-hBYu6wsKDJION72J1oZOZPe2F34dtEdHV6Vo0S_oOuXPNUoxofEXfT-cjEfT0Ycn5ORg9G049l2tBl-lebz0Qx2VieaKa6lCFYkYpv6SZ0LHGhgoz5jJUdZGiiyOpWKR0YmRTASKi0xGZc6ekkFVV3qL0CzAslgo7C8zzg2HjxyIJ0QXY8pIxh5ha2MVygmZYz2NeWF351JY0LR9X6CJC2dij_jdU4tWyOMG_Gf0gw6LMtz2Ajhn4ZyzuMk5PfISvahoz7R2waTYZzwF4hvn8DWvLQKlOCrM9TkXq6YpDientwB9Pb4NaNoDvXMgU0OfKeEOYUDPow5YD_m2hzxvVdCvA-70gBCeVO_2Fo6gdR83sNZEzckgzhKPvFqPqgKfwnS_Stcri7HEOef_wsBKlwEDizzyrB2JnbFwsxioM_NI2hujPWv271Sz71ZcHb40yXm6_T_M_5zci2z1FExJ3CGD5eVK7wKHXcoXNlz9AVbnmC8 priority: 102 providerName: Directory of Open Access Journals |
Title | Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24137103 https://www.proquest.com/docview/1443993794 https://www.proquest.com/docview/1458533032 https://pubmed.ncbi.nlm.nih.gov/PMC3796947 https://doaj.org/article/1eb678e02a8044a79a13f6588016acb1 http://dx.doi.org/10.1371/journal.pmed.1001510 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZGJyFeJu4LjGIQ4vKQKRcnTpAQ2qpOHagtFDr1LbIdp1SUpDQtYn-M38ex42YLKrCXPCRfnMg-x_5sH38HoWdgAyGNWWYLl1Fb7QTaMAhz2xcBEPzMcVMdRNMfhL0xeTcJJjtok7PVVGC5dWqn8kmNl_PDn9_P34LDv9FZG6i7eelwAeOH1hQK1JmrXRibqHLVPqn3FbzY0asuSpfMdkMamsN0fyulMVhpTf-6524t5kW5jZb-GV15abg6uYn2DM_ER5Vh3EI7Mr-NrvfNTvod9Gs0K79ik20HszzFxXoF1idLDDQWz4GC4sXF0aRc3-2dntlVlNcPeKq5eolnOa6W9F9jwK_nKyhhWXzDwCxx57KV4SLDQ16vAsPfQXm4e5GiVtkL3oQCmkKxCnQ8xy87w1531H11F41Pup87PdvkcLAFjYOV7UovDSURRHLhCo8FQAlSEjEZSGCmJPKzWMndcBYFARe-l8kw4z5zBGER99LYv4daeZHLfYQjR6XLUoL_PCIkI3CJgZBCr5NlqccDC_mbxkqEEThXeTbmid61ozDRqeo-UU2cmCa2kF2_tagEPv6DP1Z2UGOVPLe-USynifH2xJUcSIB0PBY5hDBwBtfPgOsBHQiZ4K6FHisrSqqzrnUnkxz5hAIhDmL4zFONUBIduYoBmrJ1WSanw7MrgD4NrgIaNUAvDCgroM4EM4czoOaVPlgD-byBnFbq6NuABw0gdFui8XhfedCmjkuYgyotSieIQgs92XhVot5SYYC5LNYaowl1TP6FgRmwD8zMs9D9yhPrxlKbyECpfQvRho82WrP5JJ990aLr8NEwJvTBFf7tIbrh6aQpKhLxALVWy7V8BNR1xdvoGp3QNto97g4-jNp6AQiu7z9Gbd1P_QaIaJyh |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+and+outcomes+for+late+presentation+for+HIV-positive+persons+in+Europe%3A+results+from+the+Collaboration+of+Observational+HIV+Epidemiological+Research+Europe+Study+%28COHERE%29&rft.jtitle=PLoS+medicine&rft.au=Mocroft%2C+Amanda&rft.au=Lundgren%2C+Jens+D&rft.au=Sabin%2C+Miriam+Lewis&rft.au=Monforte%2C+Antonella+d%27Arminio&rft.date=2013-09-01&rft.issn=1549-1676&rft.eissn=1549-1676&rft.volume=10&rft.issue=9&rft.spage=e1001510&rft_id=info:doi/10.1371%2Fjournal.pmed.1001510&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |